[go: up one dir, main page]

MX2024003772A - Compuestos de imidazopiridazina inhibidores de il-17. - Google Patents

Compuestos de imidazopiridazina inhibidores de il-17.

Info

Publication number
MX2024003772A
MX2024003772A MX2024003772A MX2024003772A MX2024003772A MX 2024003772 A MX2024003772 A MX 2024003772A MX 2024003772 A MX2024003772 A MX 2024003772A MX 2024003772 A MX2024003772 A MX 2024003772A MX 2024003772 A MX2024003772 A MX 2024003772A
Authority
MX
Mexico
Prior art keywords
sup
imidazopyridazine
inhibitor compounds
compounds
ameliorating
Prior art date
Application number
MX2024003772A
Other languages
English (en)
Inventor
Dongpei Wu
Xiaohua Xue
Timothy B Rhorer
Stefan Mccarver
Steven D Goldberg
Deane Gordon
Steven A Loskot
Steven P Meduna
Alexander E Valdes
Luke E Hanna
Douglas C Behenna
Kristen Song
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2024003772A publication Critical patent/MX2024003772A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente solicitud describe compuestos que tienen la siguiente fórmula: (VER FORMULA) o sales farmacéuticamente aceptables de estos, en donde R1 , R2 , R3 , y R4 se definen en la especificación, así como métodos para elaborar y usar los compuestos descritos en la presente descripción para tratar o mejorar un síndrome, trastorno y/o enfermedad mediada por la IL-17.
MX2024003772A 2021-09-27 2022-09-26 Compuestos de imidazopiridazina inhibidores de il-17. MX2024003772A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163248566P 2021-09-27 2021-09-27
US202163273422P 2021-10-29 2021-10-29
US202263367546P 2022-07-01 2022-07-01
PCT/US2022/077001 WO2023049887A1 (en) 2021-09-27 2022-09-26 Imidazopyridazine il-17 inhibitor compounds

Publications (1)

Publication Number Publication Date
MX2024003772A true MX2024003772A (es) 2024-06-19

Family

ID=83692741

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003772A MX2024003772A (es) 2021-09-27 2022-09-26 Compuestos de imidazopiridazina inhibidores de il-17.

Country Status (15)

Country Link
US (2) US12173007B2 (es)
EP (1) EP4408847A1 (es)
JP (1) JP2024536869A (es)
KR (1) KR20240082369A (es)
AU (1) AU2022349687A1 (es)
CA (1) CA3233408A1 (es)
CL (1) CL2024000867A1 (es)
CO (1) CO2024003723A2 (es)
DO (1) DOP2024000051A (es)
IL (1) IL311751A (es)
MX (1) MX2024003772A (es)
PE (1) PE20240935A1 (es)
TW (1) TW202330530A (es)
UY (1) UY39958A (es)
WO (1) WO2023049887A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY39958A (es) 2021-09-27 2023-04-28 Janssen Pharmaceutica Nv Compuestos de imidazopiridazina inhibidores de il-17
WO2023076237A1 (en) 2021-10-25 2023-05-04 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
WO2024115662A1 (en) 2022-12-02 2024-06-06 Leo Pharma A/S Small molecule modulators of il-17
WO2024163365A1 (en) * 2023-01-30 2024-08-08 Dice Alpha, Inc. Benzimidazole and aza-benzimidazole based il-17a modulators and uses thereof
CN121311483A (zh) * 2023-03-28 2026-01-09 詹森药业有限公司 含内酰胺的咪唑并哒嗪il-17抑制剂化合物
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2024215597A1 (en) * 2023-04-11 2024-10-17 Dice Alpha, Inc. Substituted 6-imidazopyridazine il-17a modulators and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214648A (zh) 2019-01-07 2022-04-16 美商美國禮來大藥廠 Il-17a抑制劑
GB201909190D0 (en) 2019-06-26 2019-08-07 Ucb Biopharma Sprl Therapeutic agents
KR20230019507A (ko) 2020-04-30 2023-02-08 얀센 파마슈티카 엔.브이. Il-17의 조절제로서의 이미다조피리다진
WO2023025783A1 (en) 2021-08-23 2023-03-02 Leo Pharma A/S Small molecule modulators of il-17
UY39958A (es) 2021-09-27 2023-04-28 Janssen Pharmaceutica Nv Compuestos de imidazopiridazina inhibidores de il-17
CN116143777A (zh) 2021-11-04 2023-05-23 四川海思科制药有限公司 一种可抑制il-17a的杂环化合物及其用途

Also Published As

Publication number Publication date
CA3233408A1 (en) 2023-03-30
PE20240935A1 (es) 2024-04-30
EP4408847A1 (en) 2024-08-07
US20230143050A1 (en) 2023-05-11
US12173007B2 (en) 2024-12-24
DOP2024000051A (es) 2024-11-15
WO2023049887A1 (en) 2023-03-30
AU2022349687A1 (en) 2024-05-16
UY39958A (es) 2023-04-28
TW202330530A (zh) 2023-08-01
US20250109137A1 (en) 2025-04-03
KR20240082369A (ko) 2024-06-10
CL2024000867A1 (es) 2024-09-23
JP2024536869A (ja) 2024-10-08
IL311751A (en) 2024-05-01
CO2024003723A2 (es) 2024-04-18

Similar Documents

Publication Publication Date Title
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2024003772A (es) Compuestos de imidazopiridazina inhibidores de il-17.
MX2024003770A (es) Compuestos de imidazopiridazina inhibidores de il-17.
CR20230310A (es) Inhibidores de prmt5
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
ZA202403388B (en) Small molecules for treatement of cancer
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
MX2022013482A (es) Compuestos utiles para inhibir la quinasa ret.
MX2025012306A (es) Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano
MX2020013570A (es) Compuestos de purinona y su uso en el tratamiento del cancer.
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
WO2024026433A3 (en) Novel dpp1 inhibitors and uses thereof
MX2024013838A (es) Compuestos y usos de estos
BRPI0412999A (pt) 2-aminotetralina substituìda para tratamento de depressão
CY1109763T1 (el) Υλικα και μεθοδος για τη θεραπεια διαταραχων πηξης
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2024005107A (es) Nuevo uso de compuesto de quinazolinona para el tratamiento de cancer.
MX2025001982A (es) Inhibidores de kif18a y usos de estos
MX2024008868A (es) Inhibidores de la apolipoproteína l1 (apol1) y métodos de uso.
WO2024099364A3 (en) Fused multicyclic compounds and their use as parp1 inhibitors
MX2025000377A (es) Preparacion de sales, esteres y conjugados estables de psilocina y usos de los mismos
MX2022003845A (es) Tratamientos cognitivos medicinales.
SE0302756D0 (sv) Novel Compounds